US Regulators Grant Landmark Approval to Injectable Nanobody Therapy for Myasthenia Gravis
The FDA has approved gefurulimab, a once-weekly self-administered nanobody, offering a more convenient treatment option for adults with generalized myasthenia gravis.
By Aylin Aksoy
Share this story
The US Food and Drug Administration has officially approved gefurulimab, marketed as Klygefa, for the treatment of generalized myasthenia gravis in adults. The regulatory decision, finalized on November 13, 2026, introduces a novel class of therapy for patients who test positive for anti-acetylcholine receptor antibodies.[1][4]
Developed by AstraZeneca's rare disease unit, Alexion, the medication is the first dual-binding nanobody to secure authorization for a neurological condition. It offers a targeted approach to halting the immune system's attack on muscle receptors, which drives the debilitating symptoms of the rare autoimmune disorder.[1][5]
Generalized myasthenia gravis disrupts the critical communication between nerves and muscles. For the 85 percent of patients who are anti-acetylcholine receptor antibody positive, the body mistakenly produces proteins that destroy the neuromuscular junction, leading to profound and often unpredictable physical limitations.[1][5]
The clinical presentation typically begins with localized weakness, manifesting as droopy eyelids, double vision, or slurred speech. As the disease progresses, patients frequently experience severe fatigue, impaired swallowing, and in the most critical cases, life-threatening respiratory failure that requires emergency intervention.[5]
A Novel Nanobody Mechanism
Gefurulimab operates by inhibiting complement component 5, a key protein in the body's terminal complement cascade. By blocking this specific pathway, the drug prevents the formation of the membrane attack complex that otherwise damages the neuromuscular junction in patients with the disorder.[1][5]
What distinguishes the new therapy is its dual-binding nanobody architecture. In addition to targeting the C5 protein, gefurulimab concurrently binds to serum albumin in the bloodstream, a mechanism that significantly extends the drug's half-life and allows it to remain active longer.[1][5]
Nanobodies, which are derived from the heavy-chain-only antibodies naturally found in camelids, are significantly smaller than traditional monoclonal antibodies. This compact size allows them to penetrate tissues more effectively and bind to hidden targets, a structural advantage that researchers believe could revolutionize treatments for various neurological conditions.[2]
This extended half-life translates directly into a more manageable dosing schedule. Following an initial weight-based loading dose, patients can self-administer the medication once a week using a prefilled subcutaneous autoinjector equipped with a needle safety device.[2][5]
"This may provide greater autonomy and a predictable treatment schedule compared with intravenously administered C5 inhibitors," said Dr. Djillali Annane, a professor of medicine at Paris-Saclay University and senior author of the pivotal clinical trial. He noted that many patients will likely welcome the shift away from clinical infusions.[2]
Prior to this approval, the FDA had authorized three other C5 inhibitors for myasthenia gravis: eculizumab, ravulizumab, and zilucoplan. However, those older therapies require either regular intravenous infusions at a medical facility or, in the case of zilucoplan, daily subcutaneous injections at home.[1][2]
Efficacy in the PREVAIL Trial
The FDA's decision was heavily informed by the results of the Phase III PREVAIL trial, a randomized, double-blind study that enrolled 260 adults across 20 countries. The participants, all of whom had anti-acetylcholine receptor antibody-positive generalized myasthenia gravis, received either weekly gefurulimab or a placebo for 26 weeks.[1][5]
The trial successfully met its primary endpoint, demonstrating a statistically significant reduction in disease severity. Patients treated with the nanobody experienced a 4.2-point improvement from baseline on the Myasthenia Gravis Activities of Daily Living scale, compared to a 2.6-point improvement in the placebo cohort.[2][5]
That 1.6-point treatment difference was clinically meaningful for a scale that ranges from zero to 24 points. Researchers noted that the functional benefits emerged rapidly, with patients reporting noticeable improvements in their daily activities as early as the first week of treatment.[1][2]
The therapeutic gains were sustained throughout the 26-week study period. Data from an ongoing open-label extension of the PREVAIL trial, published earlier this year, confirmed that the functional benefits of gefurulimab remained durable through 52 weeks of continuous weekly dosing.[1]
Secondary endpoints in the trial further reinforced the drug's efficacy. Quantitative Myasthenia Gravis scores, which measure objective muscle strength, showed significant improvement by week four in the treatment group compared to those receiving the placebo, and that advantage held steady over the subsequent months.[1][5]
Safety and Regulatory Monitoring
Because gefurulimab suppresses a specific segment of the immune system, it carries inherent infection risks. The FDA has mandated a boxed warning on the medication's label, alerting physicians and patients to the potential for serious and life-threatening infections caused by Neisseria meningitidis bacteria.[1]
To mitigate this risk, Klygefa is only available through a restricted Risk Evaluation and Mitigation Strategy program. Patients are strictly required to comply with updated recommendations for meningococcal vaccinations before initiating therapy, a standard precaution for all approved C5 inhibitors.[1]
Beyond the infection risk, the safety profile observed in the PREVAIL trial was generally favorable and consistent with older drugs in the same class. The overall percentage of participants experiencing treatment-emergent adverse events was similar between the gefurulimab and placebo groups.[1][5]
The most frequently reported side effects among patients receiving the nanobody were mild to moderate in severity. These included injection site reactions, which affected 9.9 percent of the treatment group, alongside headaches at 9.9 percent and back pain at 7.6 percent.[1]
"The safety profile was in line with earlier studies of C5 inhibitors in generalized myasthenia gravis," noted Dr. Christiane Schneider-Gold and Dr. Ralf Gold of Ruhr University Bochum in a recent editorial. They emphasized that no unexpected safety concerns emerged during the international trial.[1]
Global Rollout and Market Impact
The US authorization follows a series of recent regulatory milestones for the therapy abroad. In September 2026, Japan became the first country to grant full approval for Klygefa, authorizing its use for specific adults living with the autoimmune disorder.[5]
That same month, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending the drug's approval across the European Union. A final decision from the European Commission is expected before the end of the year, while a separate regulatory review remains underway in China.[1][5]
Market analysts anticipate that gefurulimab will capture a significant share of the myasthenia gravis treatment landscape. Despite facing a highly competitive market with several recent drug approvals, the convenience of a weekly self-injection positions the nanobody as an attractive first-line option for newly diagnosed patients.[3][6]
The approval also marks a significant victory for AstraZeneca, which acquired Alexion Pharmaceuticals in 2021 to expand its footprint in rare diseases. The company is currently evaluating gefurulimab in clinical trials for other complement-mediated disorders, hoping to leverage the nanobody platform across multiple indications.[5][6]
The approval also marks a significant victory for AstraZeneca, which acquired Alexion Pharmaceuticals in 2021 to expand its footprint in rare diseases.
For the myasthenia gravis community, the expanding roster of targeted therapies represents a paradigm shift in care. With multiple mechanisms of action now available, neurologists can increasingly tailor treatment regimens to individual patient profiles, balancing clinical efficacy with the practical demands of daily life.[1][2]
Key points
- The FDA approved gefurulimab (Klygefa) as a once-weekly subcutaneous injection for adults with anti-AChR antibody-positive generalized myasthenia gravis.
- The dual-binding nanobody blocks the C5 complement protein while binding to serum albumin to extend its half-life and enable at-home dosing.
- In the Phase III PREVAIL trial, patients taking the drug showed a clinically meaningful 1.6-point improvement over placebo on daily living assessments.
- The medication carries a boxed warning for meningococcal infections and is restricted to a Risk Evaluation and Mitigation Strategy program.
Open questions
- How gefurulimab will perform in real-world clinical settings over multiple years, particularly regarding the long-term durability of its effects.
- Whether the nanobody platform will prove equally effective and safe for other complement-mediated autoimmune disorders currently under investigation.
- The exact pricing and insurance coverage tiers for Klygefa in the US market, which will dictate patient access.
Timeline
July 2025
AstraZeneca announces that gefurulimab met its primary and secondary endpoints in the Phase III PREVAIL trial.
September 2026
Japan becomes the first country to grant regulatory approval for Klygefa.
September 2026
The European Medicines Agency's CHMP recommends the nanobody for approval across the European Union.
November 2026
The FDA officially approves Klygefa for adults with generalized myasthenia gravis in the United States.
- Clinical Neurologists
- Medical specialists who view the weekly subcutaneous option as a major step forward for patient compliance and autonomy.
- Patient Advocacy Groups
- Advocates who emphasize the quality-of-life improvements of reducing frequent clinic visits for intravenous infusions.
- Drug Safety Regulators
- Regulatory bodies focused on mitigating the severe meningococcal infection risks inherent to terminal complement inhibitors.
Perspectives this story doesn't cover
- Health Insurance Providers
- Healthcare Economists
Sources
[1]MedPage TodayClinical NeurologistsInjectable Nanobody Wins FDA Approval for Myasthenia Gravis
Read on MedPage Today →
[2]Neurology TodayClinical NeurologistsPhase 3 Findings Strong for New Complement Inhibitor for Myasthenia Gravis
Read on Neurology Today →
[3]WisevoterPatient Advocacy GroupsGefurulimab Improves Symptoms in Myasthenia Gravis
Read on Wisevoter →
[4]NewsfilterDrug Safety RegulatorsApproval of KLYGEFA, BLA #761488
Read on Newsfilter →
[5]AstraZenecaDrug Safety RegulatorsKlygefa (gefurulimab) recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis (gMG)
Read on AstraZeneca →
[6]AJMCDrug Safety RegulatorsGefurulimab Recommended for EU Approval in Generalized Myasthenia Gravis
Read on AJMC →
More in Health
See all →Clinical Trials
Mitapivat Misses Dual Sickle Cell Pain Target in Phase 3 Trial Despite Hemoglobin Increase
8 sources
Transplant Immunosuppression
Anti-CD40L Antibody Tegoprubart Outperforms Tacrolimus in Preserving Kidney Transplant Function
5 sources
Viral Hepatitis
FDA Approves Bepirovirsen as First Functional Cure for Chronic Hepatitis B
7 sources
Food Allergies
Biologic Drug Omalizumab Eliminates Severe Allergic Reactions in Alpha-Gal Syndrome Patients
6 sources
Comments
Every angle. Every day.
Get Health stories with full source coverage and perspective breakdowns, free every day.




